(Q35073327)

6 August 2017

1 reference

title

The therapeutic potential of aromatase inhibitors (English)

1 reference

6 August 2017

Miller WR

1

1 reference

6 August 2017

Jackson J

series ordinal

2

1 reference

6 August 2017

language of work or name

English

0 references

publication date

1 March 2003

1 reference

Expert Opinion on Investigational Drugs

6 August 2017

published in

1 reference

6 August 2017

volume

12

1 reference

6 August 2017

issue

3

1 reference

6 August 2017

page(s)

337-351

1 reference

Steroid hormones and cancer: (III) observations from human subjects

6 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.3.337

Medical adrenalectomy with aminoglutethimide: clinical studies in postmenopausal patients with metastatic breast carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.3.337

Exemestane: a potent irreversible aromatase inactivator and a promising advance in breast cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.3.337

Inhibition of Peripheral Aromatization of Androstenedione to Estrone in Postmenopausal Women with Breast Cancer Using Δ1Testololactone*

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.3.337

Drug and hormone interactions of aromatase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.3.337

Breast tumor aromatase: functional role and transcriptional regulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.3.337

Arimidex (ZD1033): a selective, potent inhibitor of aromatase in postmenopausal female volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.3.337

The efficacy of CGS 20267 in suppressing estrogen biosynthesis in patients with advanced stage breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.3.337

Third-line hormonal treatment with exemestane in postmenopausal patients with advanced breast cancer progressing on aminoglutethimide: a phase II multicentre multinational study. Exemestane Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.3.337

Mechanisms of action of aminoglutethimide as endocrine therapy of breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.3.337

The evolution of tamoxifen therapy in breast cancer: selective oestrogen-receptor modulators and downregulators

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.3.337

A randomised trial comparing two doses of the new selective aromatase inhibitor anastrozole (Arimidex) with megestrol acetate in postmenopausal patients with advanced breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.3.337

Phase III, multicenter, double-blind, randomized study of letrozole, an aromatase inhibitor, for advanced breast cancer versus megestrol acetate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.3.337

Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.3.337

Letrozole as primary medical therapy for locally advanced and large operable breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.3.337

Aromatase inhibitors in the treatment and prevention of breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.3.337

Neoadjuvant endocrine therapy of breast cancer: a surgical perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.3.337

Effect of neoadjuvant treatment with anastrozole on tumour histology in postmenopausal women with large operable breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.3.337

Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.3.337

Pharmacokinetics of anastrozole and tamoxifen alone, and in combination, during adjuvant endocrine therapy for early breast cancer in postmenopausal women: a sub-protocol of the 'Arimidex and tamoxifen alone or in combination' (ATAC) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.3.337

Effect of letrozole on the lipid profile in postmenopausal women with breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.3.337

A prospective study of endogenous serum hormone concentrations and breast cancer risk in post-menopausal women on the island of Guernsey

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.3.337

Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.3.337

Molecular mechanisms of estrogen carcinogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.3.337

The potential of aromatase inhibitors in breast cancer prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.3.337

Treatment of severe postmenopausal endometriosis with an aromatase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.3.337

10.1517/13543784.12.3.337

21 January 2018

Identifiers

DOI

1 reference

6 August 2017

1 reference